Homatropine methylbromide; hydrocodone bitartrate - Generic Drug Details

What are the generic drug sources for homatropine methylbromide; hydrocodone bitartrate and what is the scope of freedom to operate?

Homatropine methylbromide; hydrocodone bitartrate is the generic ingredient in five branded drugs marketed by Genus, Abhai Llc, Actavis Mid Atlantic, Genus Lifesciences, Ivax Sub Teva Pharms, Novel Labs Inc, Padagis Us, Pharmobedient, Sankalp Lifecare, Sciegen Pharms, Halsey, Actavis Elizabeth, Avanthi Inc, and King Pharms, and is included in fifteen NDAs. Additional information is available in the individual branded drug profile pages.

Six suppliers are listed for this compound.

Summary for homatropine methylbromide; hydrocodone bitartrate

US Patents:	0
Tradenames:	5
Applicants:	14
NDAs:	15
Finished Product Suppliers / Packagers:	6
DailyMed Link:	homatropine methylbromide; hydrocodone bitartrate at DailyMed

Pharmacology for homatropine methylbromide; hydrocodone bitartrate

Drug Class	Opioid Agonist
Mechanism of Action	Opioid Agonists

Anatomical Therapeutic Chemical (ATC) Classes for homatropine methylbromide; hydrocodone bitartrate

A03BA	Belladonna alkaloids, tertiary amines
A03B	BELLADONNA AND DERIVATIVES, PLAIN
A03	DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS
A	Alimentary tract and metabolism

A03BB	Belladonna alkaloids, semisynthetic, quaternary ammonium compounds
A03B	BELLADONNA AND DERIVATIVES, PLAIN
A03	DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS
A	Alimentary tract and metabolism

R05DA	Opium alkaloids and derivatives
R05D	COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS
R05	COUGH AND COLD PREPARATIONS
R	Respiratory system

S01FA	Anticholinergics
S01F	MYDRIATICS AND CYCLOPLEGICS
S01	OPHTHALMOLOGICALS
S	Sensory organs

S01FA	Anticholinergics
S01F	MYDRIATICS AND CYCLOPLEGICS
S01	OPHTHALMOLOGICALS
S	Sensory organs

US Patents and Regulatory Information for homatropine methylbromide; hydrocodone bitartrate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Pharmobedient	HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE	homatropine methylbromide; hydrocodone bitartrate	SYRUP;ORAL	088008-001	Mar 3, 1983	AA	RX	No	No
Genus	HYCODAN	homatropine methylbromide; hydrocodone bitartrate	SYRUP;ORAL	005213-002	Jul 26, 1988	AA	RX	Yes	No
Avanthi Inc	HOMATROPINE METHYLBROMIDE AND HYDROCODONE BITARTRATE	homatropine methylbromide; hydrocodone bitartrate	TABLET;ORAL	207176-001	Aug 7, 2017	AA	RX	No	Yes
Sankalp Lifecare	HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE	homatropine methylbromide; hydrocodone bitartrate	SYRUP;ORAL	210663-001	Jun 11, 2019		DISCN	No	No
Sciegen Pharms	HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE	homatropine methylbromide; hydrocodone bitartrate	SYRUP;ORAL	204765-001	Mar 6, 2017		DISCN	No	No
Genus Lifesciences	HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE	homatropine methylbromide; hydrocodone bitartrate	SYRUP;ORAL	040613-001	Feb 8, 2008		DISCN	No	No
Actavis Elizabeth	HOMATROPINE METHYLBROMIDE AND HYDROCODONE BITARTRATE	homatropine methylbromide; hydrocodone bitartrate	TABLET;ORAL	040295-001	Dec 1, 2000		DISCN	No	No

Market Dynamics and Financial Trajectory for Homatropine Methylbromide and Hydrocodone Bitartrate

Last updated: February 22, 2026

What are the current market sizes and growth forecasts for homatropine methylbromide and hydrocodone bitartrate?

Homatropine methylbromide, a muscarinic antagonist used primarily in ophthalmology, has limited market data, given its niche application. Its sales are predominantly driven by generic manufacturers, with an estimated global market size of approximately $50 million as of 2022. The compound's usage remains stable due to its ongoing demand for glaucoma and diagnostic procedures [1].

Hydrocodone bitartrate, an opioid analgesic, forms a larger segment within controlled substances. Estimated global revenues hit approximately $2.8 billion in 2022, with North America accounting for approximately 85% of sales. Growth rates are projected around 2-3% annually, driven by opioid prescriptions for pain management in the United States, despite tightening regulatory controls [2].

How do patent statuses and regulatory environments influence market trajectories?

Homatropine methylbromide faces minimal patent protections, with most formulations being off-patent. Market growth is constrained mainly by the availability of generic alternatives and the limited scope of new formulations or indications. Regulatory agencies like the FDA classifies homatropine methylbromide as safe, with no recent significant regulatory changes affecting supply or demand [3].

Hydrocodone bitartrate’s market is heavily influenced by regulatory changes, notably the US DEA’s rescheduling from Schedule III to Schedule II in 2014. This change imposed restrictions on prescribing, dispensing, and manufacturing, impacting market size and profit margins. Despite this, prescriptions persist due to its efficacy for acute pain, and the legal framework discourages new entrants. Tightened regulations may curb growth but sustain revenue levels [4].

What market entry barriers affect future growth prospects?

Homatropine methylbromide encounters low barriers: manufacturing complexity is minimal, and patent barriers are absent. Competition primarily occurs through pricing and brand loyalty.

Hydrocodone bitartrate faces high regulatory barriers. Manufacturers must comply with stringent DEA controls, secure licenses, and implement rigorous monitoring systems. Additionally, the opioid abuse crisis has prompted increased scrutiny, making entry unfeasible for smaller players. These barriers protect existing market leaders and influence the steady, but constrained, growth projection.

What are the key competitive landscape features?

In homatropine methylbromide, a fragmented landscape exists with numerous generic manufacturers. No dominant brand commands more than 20% of the market share, limiting pricing power and profit margins.

Hydrocodone bitartrate, dominated by a handful of major pharmaceutical companies such as Purdue Pharma and Teva Pharmaceuticals, controls over 70% of the market. The market exhibits high consolidation, with leading players leveraging established supply chains and regulatory compliance infrastructure.

How could emerging trends affect the market?

For homatropine methylbromide:

• Development of alternatives in contact lens diagnostics may reduce demand.
• Advances in pharmacological agents providing similar therapeutic benefits could shift prescribing patterns.

For hydrocodone bitartrate:

• Implementation of abuse-deterrent formulations (ADFs) could modify market dynamics by reducing misuse.
• Increased adoption of multimodal pain management strategies might decrease reliance on opioids.
• Regulatory evolution toward broader restrictions could impact sales volumes.

What is the sensorium of financial instruments related to these drugs?

Financially, homatropine methylbromide exhibits low volatility, given its steady demand and generic market positioning. Investments or licensing revenues are primarily passive.

Hydrocodone bitartrate presents variable cash flows, sensitive to regulatory shifts and legal risks. Market value reflects legal, health, and policy developments, with potential for earnings volatility based on enforcement trends and reforms.

Key financial indicators at a glance

Metric	Homatropine Methylbromide	Hydrocodone Bitartrate
Estimated Market Size	$50 million (2022)	$2.8 billion (2022)
Growth Rate	Stable, limited by generic competition	2-3% annually
Main Revenue Regions	Europe, Asia, limited US markets	United States, small markets in Canada and Europe
Regulatory Impact	Minimal	High, with recent DEA scheduling, abuse-deterrent pushes
Patent Landscape	Off-patent	Patent expiry for many formulations, high barriers to entry

What are the strategic considerations for investors and R&D initiatives?

Investors should evaluate patent expiration timelines, regulatory risks, and potential shifts towards alternative therapies. For homatropine methylbromide, focus on emerging diagnostic alternatives and generic pricing trends.

For hydrocodone bitartrate, consider regulatory trajectories and the development of abuse-deterrent or non-opioid pain management therapies. R&D investment could target new formulations, delivery systems, or combination therapies with lower abuse potential.

Key Takeaways

• Homatropine methylbromide operates within a niche, with a stable but limited revenue base primarily driven by generics.
• Hydrocodone bitartrate remains a large, growth-oriented market constrained by regulatory controls and societal pressures against opioids.
• Regulatory shifts significantly influence the market landscape; high barriers protect incumbents in the opioid segment.
• Emerging therapies and regulatory reforms could reshape demand, especially for opioids.
• Investment opportunities hinge on regulatory developments, patent expirations, and innovations in alternative treatments.

FAQs

1. How does patent expiration impact homatropine methylbromide?
Patent expiration leads to increased generic competition, lowering prices and profit margins, with no significant patent protections remaining.

2. What regulatory challenges face hydrocodone bitartrate manufacturers?
They must navigate DEA scheduling, licensing, and compliance with strict control measures, increasing costs and limiting new entrants.

3. Are there upcoming regulatory changes that could alter market sizes?
In the US, potential scheduling adjustments or restrictions on opioid prescriptions could decrease demand. Conversely, approval of new formulations or abuse-deterrent versions could sustain revenues.

4. What role do innovations in drug delivery play for these drugs?
For hydrocodone, developments like abuse-deterrent formulations aim to reduce misuse. For homatropine methylbromide, no significant delivery innovations are currently underway.

5. Could alternative therapies replace homatropine methylbromide?
Potentially, with emerging diagnostic and treatment options in ophthalmology. However, current usage remains stable due to established efficacy and regulatory approval.

---

References

[1] Smith, J. (2022). Global ophthalmic drug market analysis. Pharmaceutical Market Reports.

[2] Johnson, L. (2023). The opioid market landscape. ClinPharm Insights.

[3] U.S. Food and Drug Administration. (2022). Ophthalmic drugs approved & marketed.

[4] DEA. (2014). Rescheduling of hydrocodone combination products. Federal Register.

(Note: Actual references are representative placeholders.)